DiaSorin SpA

Common Name

DiaSorin

Country

Italy

Sector

Healthcare

Industry

Diagnostics & Research

Employees

3,280

Ticker

DIA

Exchange

EURONEXT MILAN

Website

int.diasorin.com

Description

Diasorin S.p.A. is a global leader in the biotechnology sector, specializing in the development, production, and marketing of diagnostic tests tailored to a variety of fields. These include infectious... Show more

Income Statement Balance Sheet Group Entities

DiaSorin's Financial Statements Preview

Below are the financial statements of DiaSorin, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?

Learn More

All figures in millions of EUR	2024 as of 2024-12-31	2023 as of 2023-12-31
Assets	—	—
Non-current assets	—	—
Property, plant and equipment	271.36^a	256.29^a
Goodwill	846.86^a	799.37^a
Intangible assets	1,181.63^a	1,125.61^a
Equity investments	0.03^a	0.03^a
Deferred-tax assets	31.6^a	31.81^a
Other non-current assets	2.7^a	2.76^a
Other non-current financial assets	3.56^a	12.89^a
Total non-current assets	2,337.74^a	2,228.75^a
Current assets	—	—
Inventories	344.04^a	315.5^a
Trade receivables	194.7^a	198.56^a
Other current assets	35.18^a	65.24^a
Other current financial assets	49^a	123.08^a
Cash and cash equivalents	344.27^a	280.31^a
Total current assets	967.18^a	982.69^a
Total assets	3,304.92^a	3,211.44^a
Liabilities and shareholders’ equity	—	—
Shareholders’ equity	—	—
Share capital	55.95^a	55.95^a
Treasury shares	-251.78^a	-296.8^a
Additional paid-in capital	18.16^a	18.16^a
Statutory reserve	11.19^a	11.19^a
Other reserves and retained earnings	1,779.3^a	1,590.27^a
Net profit for the year	188.11^a	159.85^a
Total shareholders’ equity of the group	1,800.92^a	1,538.61^a
Minority interest in other reserves and retained earnings	-0.64^a	0.76^a
Minority interest in net result	-1.25^a	-1.4^a
Minority interest in shareholders’ equity	-1.9^a	-0.64^a
Total consolidated shareholders’ equity	1,799.02^a	1,537.97^a
Non-current liabilities	—	—
Non-current financial liabilities	966.78^a	1,083.01^a
Provisions for employee benefits	31.94^a	32.31^a
Deferred-tax liabilities	199.57^a	199.6^a
Provisions for risks and charges	22.73^a	27.7^a
Other non-current liabilities	9.58^a	10.74^a
Total non-current liabilities	1,230.6^a	1,353.35^a
Current liabilities	—	—
Trade payables	99.52^a	100.71^a
Other current liabilities	109.93^a	100.36^a
Current tax liabilities	18.07^a	9.4^a
Current financial liabilities	47.78^a	109.65^a
Total current liabilities	275.3^a	320.12^a
Total liabilities	1,505.9^a	1,673.47^a
Total shareholders’ equity and liabilities	3,304.92^a	3,211.44^a

Download Data

Verified Sources Behind DiaSorin’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore DiaSorin’s data sources below and access millions more through our Disclosure Search.

a. DiaSorin's Annual Report 2024

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

DiaSorin SpA

DiaSorin's Financial Statements Preview

Verified Sources Behind DiaSorin’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

Veracyte Inc

Lonza Group AG

Charles River Laboratories International Inc

Revvity Inc

Biomerieux SA

Quest Diagnostics Inc